KOSPIBiotech & Pharma234080

JW Lifescience

₩10,620▲ 0.57%2026-11-18 close
Market Cap
₩168.2B
Turnover
₩100M
Volume
10K
Shares out.
15.8M
PER
5.7×
PBR
0.7×
EPS
₩1,855
Dividend Yield
5.18%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩550 per share · Prices as of the 2026-11-18 close

01

Report overview

JW Lifescience: Revenue Growth, Uneven Profit Trend

JW Lifescience grew revenue for three straight years through 2025, yet operating profit and net profit attributable to controlling shareholders fell in 2025, and in 2026 quarterly sales have slipped while quarterly operating profit has kept rising.

  1. 1

    Sales in 2025 reached KRW 257.8 billion, up 15.9% from the prior year, while operating profit fell 7.3% to KRW 33.2 billion.

  2. 2

    Quarterly sales declined for three consecutive quarters from the first quarter of 2026 through the third quarter, while operating profit rose for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026.

  3. 3

    Net profit attributable to controlling shareholders totaled KRW 28.7 billion over the last four quarters (fourth quarter of 2025 to third quarter of 2026), and third-quarter 2026 operating profit of KRW 9.4 billion was up 32.9% year on year.

  4. 4

    The company attributed the 2025 profit decline to higher one-off selling and administrative costs and to a base effect from temporary derivative trading gains recorded in 2024.

  5. 5

    Brokerage research has cited the classification of IV fluids as essential medicines, which keeps them outside the generic drug price cut campaign, as a policy-side strength.

02

Business structure

JW Lifescience is an IV fluid specialist that produces basic IV fluids, total parenteral nutrition (TPN) solutions, special IV fluids and nutritional IV fluids. A company profile describes its three-chamber TPN product as one made by only a few companies worldwide.

According to a brokerage report from May 2026, 2025 TPN sales reached KRW 84.8 billion, up 11.7% year on year. In the same data, 2025 special IV fluid sales fell 9.4% on base effects and other factors, while nutritional IV fluid sales rose 25.8% to KRW 19.0 billion.

Sales depend heavily on affiliates: a February 2024 brokerage analysis said 82.2% of third-quarter 2023 sales ran through JW Pharmaceutical, while contract manufacturing (CMO) accounted for 12.4%. The CMO business serves about 20 customers, including SK Chemicals and Hanall Biopharma.

Overseas, the company signed an exclusive supply agreement with US-based Baxter in 2013 and became the first in Asia to receive EUGMP approval for nutritional IV fluids in 2018.

The 2025 consolidated results included the effect of consolidating JW Biosciences, which a brokerage expects to fade in 2026 as growth normalizes. The company competes with several domestic IV fluid makers, and its business structure differs from that of large biologics CMO Samsung Biologics.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩62.6B₩7.1B11.3%
2025Q4₩64.3B₩7.6B11.8%
2026Q1₩63.5B₩9.3B14.7%
2026Q2₩63.2B₩9.3B14.8%
2026Q3₩62.7B₩9.4B15.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩188.9B₩27.1B₩15B14.3%10.7%80.2%
2023₩206.9B₩30.9B₩28.1B14.9%17.7%60.5%
2024₩222.5B₩35.9B₩44B16.1%21.9%62.3%
2025₩257.8B₩33.2B₩28.6B12.9%13.0%44.3%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-16

04

Earnings analysis

On a DART-disclosed annual basis, revenue rose from KRW 188.9 billion in 2022 to KRW 257.8 billion in 2025, with three consecutive years of growth from 2023 to 2025. Revenue was KRW 206.9 billion in 2023, up 9.5%, and KRW 222.5 billion in 2024, up 7.5%.

Operating profit peaked at KRW 35.9 billion in 2024, the largest year in the 2022 to 2025 span, and fell 7.3% to KRW 33.2 billion in 2025. The operating margin moved from 14.3% in 2022 to 14.9% in 2023 and 16.1% in 2024, then dropped to 12.9% in 2025.

The company said 2025 sales rose on new product sales and better subsidiary performance, while one-off selling and administrative costs such as service fees increased. A brokerage report from early 2026 flagged the cost burden from a weaker won as a variable for profitability.

Net profit attributable to controlling shareholders rose from KRW 15 billion in 2022 to KRW 44 billion in 2024, then fell 35.0% to KRW 28.6 billion in 2025. The 2024 figure included temporary derivative trading gains, according to the company, so year-on-year comparisons based on 2024 need that context.

The balance sheet strengthened: the debt ratio fell from 80.2% in 2022 to 44.3% in 2025, with year-end 2025 total equity of KRW 220.6 billion and total liabilities of KRW 97.6 billion. Operating cash flow went from KRW 14.1 billion in 2022 to KRW 50.7 billion in 2024 and KRW 40.5 billion in 2025.

On a quarterly basis, revenue peaked at KRW 64.3 billion in the fourth quarter of 2025 and then declined for three consecutive quarters to KRW 62.7 billion in the third quarter of 2026.

Operating profit rose from KRW 7.08 billion in the third quarter of 2025 to KRW 9.4 billion in the third quarter of 2026, a fourth consecutive quarterly increase.

Net profit attributable to controlling shareholders was highest at KRW 8.01 billion in the second quarter of 2026 and fell 5.5% to KRW 7.57 billion in the third quarter. First-quarter 2026 disclosed revenue of KRW 63.5 billion came in below a May 2026 brokerage estimate of KRW 72.1 billion.

05

Industry analysis

The domestic IV fluid market is viewed as relatively insulated from the government's generic drug price cut push because IV fluids are classified as essential medicines. A brokerage report from May 2026 said IV fluids are excluded from the price cut targets and therefore receive policy protection.

According to the same report, demand for total parenteral nutrition keeps rising with an aging population, more cancer patients, expanded surgery and chemotherapy, and more patients with gastrointestinal dysfunction.

Competition in the TPN market has intensified, and a 2025 brokerage report said this slowed sales growth. On costs, a stronger won is a burden, and the brokerage said a higher share of high-margin products could improve profitability.

A 2024 brokerage report said that expanding production of nutritional IV fluids, which clinics and smaller hospitals use widely, supported sales. A report also noted that expanded TPN capacity at the Dangjin plant raised output by 37%. FnGuide profiles the company as the leading domestic TPN maker by market share.

Given its IV fluid focus, the business overlaps little with Samsung Biologics or Celltrion. On policy, brokerage research argues that changes to drug pricing have limited direct effects on IV fluids.

06

Outlook

Among the brokerage estimates confirmed, a May 2026 brokerage report projected 2026 consolidated revenue of KRW 273.9 billion, up 6.2%, and operating profit of KRW 35.6 billion, up 7.1%. The same report forecast 2026 TPN sales of KRW 90.1 billion, up 6.3%, and nutritional IV fluid sales of KRW 20.2 billion, up 6.1%.

These estimates may differ from disclosed results: first-quarter 2026 disclosed revenue of KRW 63.5 billion fell short of the May 2026 estimate of KRW 72.1 billion, and disclosed revenue has declined for three consecutive quarters through the third quarter.

A 2025 brokerage report said the company is pushing the launch and wider sale of new TPN products. The May 2026 report attributed the expected profit improvement mainly to growth in higher-margin products.

In early 2026, reports said the company was reviewing the construction of cogeneration and self-generation facilities to reduce energy costs for IV fluid production. Around the same time, a proposal to add energy business to the articles of incorporation was reported as set to go before the regular shareholder meeting.

On growth, a brokerage expects the 2025 consolidation effect to fade, returning 2026 growth to a normal pace. The next confirmable checkpoint is the 2026 annual report, which will show full-year revenue and operating margin.

With the 2025 operating margin at 12.9%, the 2026 margin level will indicate whether profitability has recovered.

07

Valuation

PER
5.7×
PBR
0.7×
ROE
12.8%
EPS
₩1,855
BPS
₩15,138
Dividend per share
₩550

Valuation is usually read through both earnings-based and book-value-based multiples. The price-to-book ratio sits below 1x, which means the share price trades under book value per share. A May 2026 brokerage report described the share price as low relative to fundamentals based on 2026 estimated earnings.

The same report cited the year-end dividend appeal as an investment factor. An August 2026 press report noted that the dividend per share was raised even though net profit fell 35%.

Over several years, the operating margin rose from 14.3% in 2022 to 16.1% in 2024 before falling to 12.9% in 2025, so 2025 is the year the profit trend turned. Multiples move with the share price and with each earnings release, so they should be read alongside the profit trend.

The brokerage view rests on estimated earnings, so it becomes clearer when compared with confirmed 2026 profit in the annual report.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-16

08

Bull factors

Policy-protected IV fluid sales

A May 2026 brokerage report cited the essential-medicine classification of IV fluids, which keeps them outside the generic drug price cut push, as a strength. The report used this point to explain a relatively steady earnings path for the sector in 2026. It also argued that drug pricing changes have limited direct impact on IV fluid sales.

TPN-led demand growth

According to the May 2026 brokerage report, 2025 TPN sales reached KRW 84.8 billion, up 11.7%. The report links prescription demand to an aging population, more cancer patients and a wider base of patients with gastrointestinal dysfunction. It forecasts 2026 TPN sales of KRW 90.1 billion, up 6.3%.

Profit recovery and balance sheet room

Operating profit rose for four consecutive quarters from the fourth quarter of 2025 through the third quarter of 2026, and third-quarter 2026 operating profit was up 32.9% year on year.

The debt ratio fell from 80.2% in 2022 to 44.3% in 2025, and operating cash flow of KRW 40.5 billion in 2025 exceeded the KRW 14.1 billion recorded in 2022. A brokerage cited the year-end dividend appeal as an investment factor.

09

Bear factors

Profitability setback in 2025

Operating profit in 2025 was KRW 33.2 billion, down 7.3%, and the operating margin fell to 12.9% from 16.1% in 2024. The company pointed to higher one-off selling and administrative costs as a main cause. Net profit attributable to controlling shareholders fell 35.0% to KRW 28.6 billion in the same year.

Three straight quarters of sales declines

Quarterly revenue slid from KRW 64.3 billion in the fourth quarter of 2025 to KRW 63.5 billion, KRW 63.2 billion and KRW 62.7 billion across the first three quarters of 2026. First-quarter 2026 disclosed revenue came in below a May 2026 brokerage estimate of KRW 72.1 billion. A brokerage attributes the slowdown partly to the fading subsidiary consolidation effect.

TPN competition and currency cost pressure

A 2025 brokerage report said intensifying competition in the TPN market slowed sales growth. A weaker won adds to costs and was flagged as a variable for 2026 profitability. The 2024 net profit figure includes temporary derivative trading gains, which affects how later changes should be read.

10

Risk factors

Costs, currency and energy

A February 2026 press report noted that IV fluid production is energy-intensive, making the cost structure sensitive to energy prices. Brokerages flagged a weaker won as a cost burden. The company was reported to be reviewing facilities to reduce energy costs.

Dependence on affiliated distribution

A February 2024 brokerage analysis said 82.2% of third-quarter 2023 sales ran through JW Pharmaceutical. Because the model relies on affiliate distribution, changes in that partner's sales strategy could directly affect top-line results. Contract manufacturing accounted for a smaller 12.4% share over the same period.

Policy and competitive environment

Brokerages note that IV fluids are outside the price cut push while competition in TPN is intensifying. The policy protection tied to the essential-medicine classification could change if the regulatory framework is revised. In 2025, one-off costs and base effects reduced net profit, which tested the stability of earnings power.

11

What to watch next

  1. Around February 2027

    Based on the precedent of the fiscal 2025 year-end dividend decision disclosed on February 10, 2026, the year-end dividend decision for fiscal 2026 is the next check. Because dividends held up despite lower 2025 profit, the key point is how payouts track earnings.

  2. Late March 2027

    This is the filing deadline for the 2026 annual report, 90 days after fiscal year-end. The check is whether confirmed 2026 revenue exceeds the KRW 257.8 billion of 2025 and whether the operating margin recovers from 12.9%. Fourth-quarter 2026 operating profit compared with KRW 7.58 billion in the fourth quarter of 2025 is also a checkpoint.

  3. Mid-May 2027

    This is the filing deadline for the first-quarter 2027 quarterly report, 45 days after quarter-end. The checkpoints are whether revenue breaks the three-quarter decline that began in 2026 and whether TPN sales growth holds.

12

Overall view

JW Lifescience has grown sales for three straight years since 2023, yet in 2025 the overlap of the subsidiary consolidation effect and one-off costs reduced operating profit and net profit attributable to controlling shareholders.

In 2026, quarterly sales have declined for three consecutive quarters while operating profit has risen for four, so revenue and profit are moving in different directions.

Strengths include policy protection for IV fluids under the drug price cut push, TPN-led demand growth, a lower debt ratio and steady operating cash flow. Weaknesses include the 2025 margin decline, intensifying TPN competition, currency-driven cost pressure and reliance on affiliated distribution.

Brokerage estimates point to 2026 revenue growth, but first-quarter 2026 disclosed revenue came in below the May 2026 estimate. On valuation, the price-to-book ratio sits below 1x, and one brokerage described the share price as low relative to fundamentals based on estimated 2026 earnings.

The next checkpoints are full-year 2026 revenue and operating margin in the annual report, and the revenue trend in the first-quarter 2027 report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. newsprime.co.kr
  2. vegannews.co.kr
  3. etoday.co.kr
  4. comp.fnguide.com
  5. hankyung.com
  6. ssl.pstatic.net
  7. hkn24.com
  8. smartbizn.com
  9. press9.kr
  10. newsthevoice.com
  11. jw-pharma.co.kr
  12. medicopharma.co.kr
  13. jw-lifescience.co.kr
  14. v.daum.net
  15. view.asiae.co.kr
  16. alphasquare.co.kr
  17. ebn.co.kr

Report written 2026-11-16 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis